Article
ERBB2 mutations define a subgroup of endometrial carcinomas associated with high tumor mutational burden and the microsatellite instability-high (MSI-H) molecular subtype.
Molecular oncology - 1 Oct 2024
Brodeur Melica Nourmoussavi, Selenica Pier, Ma Weining, Moufarrij Sara, Dagher Christian, Basili Thais, Abu-Rustum Nadeem R, Aghajanian Carol, Zhou Qin, Iasonos Alexia, Ellenson Lora H, Weigelt Britta, Chui M Herman
Abstract excerpt
Anti-HER2 therapy is indicated for erb-b2 receptor tyrosine kinase 2 (ERBB2)-amplified/overexpressing endometrial carcinoma (EC). Mutations constitute another mode of ERBB2 activation, but only rare ERBB2-mutated ECs have been reported. We sought to characterize the clinicopathologic and genetic features of ERBB2-mutated EC. From an institutional cohort of 2638 ECs subjected to clinical tumor-normal panel...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.